Oral contraceptive use and premenopausal breast cancer in Sweden and Norway: possible effects of different pattern of use. 1989

E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
Institutt for Samfunnsmedisin, Tromsø, Norway.

Different use of oral contraceptives (OCs) in relation to reproductive histories and age might explain the conflicting results found in studies from different countries of OC use and premenopausal breast cancer. A population-based case-control study in Sweden and Norway has been analysed separately for the two countries. The study consists of 317 Swedish and 105 Norwegian cases diagnosed 1984-1985 with 317 Swedish and 210 Norwegian controls. The results for each country separately are consistent with the joint analysis showing increased risk for breast cancer with increased duration of OC use with the exception of that for women with more than 15 years since first use. The relative risk of breast cancer for more than four years of use among Norwegian women was 0.6 (95% confidence internal (Cl), 0.2-1.8). In both countries there was a non-significant higher risk associated with increasing duration of use before first full-term pregnancy. Analyses for surveillance bias show no evidence of bias as explanation for the association between total duration of OC use and breast cancer.

UI MeSH Term Description Entries
D009664 Norway A country located in northern Europe, bordering the North Sea and the Atlantic Ocean, west of Sweden. The capital is Oslo. Kingdom of Norway
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012306 Risk The probability that an event will occur. It encompasses a variety of measures of the probability of a generally unfavorable outcome. Relative Risk,Relative Risks,Risk, Relative,Risks,Risks, Relative
D013548 Sweden Country in northern Europe, bordering the Baltic Sea, between Finland and Norway. The capital is Stockholm.
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016001 Confidence Intervals A range of values for a variable of interest, e.g., a rate, constructed so that this range has a specified probability of including the true value of the variable. Confidence Interval,Interval, Confidence,Intervals, Confidence

Related Publications

E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
January 1991, Cancer detection and prevention,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
July 1989, Journal of the National Cancer Institute,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
November 1985, British journal of cancer,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
March 1985, Lancet (London, England),
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
December 1979, The Journal of reproductive medicine,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
March 2007, Mayo Clinic proceedings,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
September 2022, JAMA network open,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
November 1987, British journal of cancer,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
February 1984, American journal of epidemiology,
E Lund, and O Meirik, and H O Adami, and R Bergstrøm, and T Christoffersen, and P Bergsjø
November 2016, Acta obstetricia et gynecologica Scandinavica,
Copied contents to your clipboard!